The coronavirus pandemic wiped billions from global drug stock valuations in the first quarter, with the few gainers failing to offset huge losses elsewhere.
Using drugs that can cause or exacerbate lung infections to treat the novel coronavirus – what could go wrong?
For $3m Verastem adds to its pipeline another asset that a bigger company had given up on.
If the first three quarters of 2019 were dominated by pricing fears, the last saw a remarkable comeback for biopharma.
Novo Nordisk took an early step towards genome editing with yesterday’s Bluebird tie-up, and isn’t ruling out a move into conventional gene therapies.
Non-US big biopharma stocks led the way in the third quarter, suggesting that those looking for investment gains would do best to search further afield.
A phase III win for Roche’s satralizumab has added to Alexion’s Soliris woes.
The Astrazeneca spinout is plugging data with its rare disease contender inebilizumab, but Alexion’s Soliris is one step ahead.
Promising mid-stage data with Merck KGaA’s evobrutinib in multiple sclerosis could help the German group carve out a niche for its BTK inhibitor – unless bigger players…